NNC0143-0406

DRUG2 trials

Sponsors

Novo Nordisk A/S

Conditions

DiabetesDiabetes Mellitus, Type 1

Phase 1

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes

CompletedNCT02612844

Novo Nordisk A/SDiabetes, Diabetes Mellitus, Type 1

Start: 2015-11-30End: 2016-06-30Updated: 2017-12-06

A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus

CompletedNCT02938572

Novo Nordisk A/SDiabetes, Diabetes Mellitus, Type 1

Start: 2016-10-19End: 2017-07-04Updated: 2018-02-26